Free Trial

This company has been marked as potentially delisted and may not be actively trading.

AEX:BTH

Breathtec Biomedical (BTH) Stock Price, News & Analysis

About Breathtec Biomedical Stock (AEX:BTH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
101,838 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Breathtec Biomedical, Inc., through its subsidiary, Nash Pharmaceuticals Inc., focuses on drug repurposing in the areas of non-alcoholic steatohepatitis, chronic kidney, and inflammatory bowel diseases. Its lead compound is the NP-178 for use in the treatment of ulcerative colitis. The company also develops NP-120 that is clinically used for the treatment of ulcerative colitis and Crohn's diseases. Breathtec Biomedical, Inc. is headquartered in Vancouver, Canada.

Receive BTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Breathtec Biomedical and its competitors with MarketBeat's FREE daily newsletter.

BTH Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

BTH Stock Analysis - Frequently Asked Questions

Industry, Sector and Symbol

Stock Exchange
AEX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
AEX:BTH
CIK
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (AEX:BTH) was last updated on 5/14/2025 by MarketBeat.com Staff
From Our Partners